Low-dose aspirin (75–100mg) reduces atherothrombotic events in secondary prevention via irreversible platelet COX-1 inhibition. Current AHA/ACC guidelines no longer recommend it for routine primary prevention in low-to-intermediate risk patients.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.